A related commentary notes that metformin did not lead to substantial benefit versus placebo for key secondary outcomes such as HbA1c and insulin requirement after 3 years. The authors agrees with the investigators that these results do not support use of metformin to improve glycaemic control in adults with long-standing type 1 diabetes, with perhaps a call for removal of current recommendations.